贝伐珠单抗联合TP方案治疗卵巢癌的临床研究

Clinical study of bevacizumab combined with TP regimen in the treatment of ovarian cancer

目的探讨贝伐珠单抗注射液联合紫杉醇+顺铂(TP)方案治疗对卵巢癌患者肿瘤标记物、机体免疫功能的影响。方法选取2016年1月至2018年6月西安市妇幼保健院、西安市第五医院收治的92例卵巢癌患者作为研究对象。运用随机数字表法将其分成观察组(n=46)与对照组(n=46)。观察组采取贝伐珠单抗注射液+TP方案治疗,对照组仅给予TP方案治疗,连续治疗6个周期后评估两组疗效。治疗前后检测两组血清肿瘤标记物[人附睾蛋白4(HE4)、糖类抗原125(CA125)、癌胚抗原(CEA)]水平及外周血T淋巴细胞亚群(CD3^+、CD4^+、CD8^+)表达水平。并统计两组不良反应发生情况。结果观察组总有效率显著高于对照组(P<0.05)。两组治疗后血清HE4、CA125、CEA水平均较治疗前有显著降低,且观察组下降更显著(P<0.05)。两组治疗后外周血CD3^+、CD4^+、CD8^+水平均显著低于治疗前(P<0.05),但上述免疫功能参数组间对比,差异均无统计学意义(P>0.05)。观察组脱发、恶心呕吐、肌肉关节痛等不良反应发生率较对照组差异亦均无统计学意义(P>0.05)。结论贝伐珠单抗注射液联合TP方案治疗卵巢癌可取得满意疗效,患者耐受性较好,能显著降低患者血清中相关肿瘤标记物水平,但不会造成机体免疫功能的进一步损伤,又不额外增加治疗的不良反应。

Objective To explore the effect of bevacizumab injection plus TP regimen chemotherapy(paclitaxel injection+cisplatin injection)on the tumor markers and immune function in patients with ovarian cancer.Methods A total of 92 patients with ovarian cancer admitted to Xi′an Maternal and Child Health Hospital and Xi′an Fifth Hospital from January 2016 to June 2018 were selected as research objects,and divided into observation group(n=46)and control group(n=46)by random number table method.The observation group was treated with Bevacizumab injection plus TP regimen,while the control group was treated with TP regimen only.After 6 consecutive cycles of treatment,the efficacy of the two groups was evaluated.The levels of tumor markers[human epididymal protein 4(HE4),carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA)]and the expression levels of peripheral blood T lymphocyte subsets(CD3^+、CD4^+、CD8^+)in the two groups were measured before and after treatment.The occurrence of adverse reactions in the two groups was also recorded.Results The total effective rate in the observation group was significantly higher than in the control group(P<0.05).After treatment,serum HE4,CA125 and CEA levels in both groups were significantly decreased compared with those before treatment,and the decrease was more significant in the observation group(P<0.05).After treatment,the levels of CD3^+、CD4^+and CD8^+in peripheral blood of the two groups were significantly lower than those before treatment(P<0.05),but the differences of the above immune function parameters between groups were not statistically significant(P>0.05).Compared with the control group,the incidence of adverse reactions such as hair loss,nausea and vomiting,muscle and joint pain in the observation group was also not statistically significant(P>0.05).Conclusions Bevacizumab injection plus TP regimen chemotherapy can achieve satisfying effect in treating patients with ovarian cancer,in lowering related tumor markers in patients without further damage to their immune function or leading to additional side effect,and it′s well tolerated by the patients.